Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res. 2023 Apr 14;29(8):1377-1380. doi: 10.1158/1078-0432.CCR-22-3882.
Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies. See related article by Klümper et al., p. 1496.
临床数据显示，大多数膀胱癌过度表达NECTIN-4，而依维莫司（EV）对此有效。最近的一篇文章表明，NECTIN-4 的膜表达随着转移性疾病的进展而变化，转移性活检中低 NECTIN-4 表达可能与 EV 耐药有关。这些数据表明需要将 NECTIN-4 表达纳入未来的生物标志物策略中。Klümper 等人的相关文章见第 1496 页。
